Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Children Aged 6-35 Months
NCT03859141Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quadrivalent influenza vaccine in seasonal influenza (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Geometric Mean Titer Ratio (Experimental/Control) and Seroconversion Rate Difference (Experimental - Control). Started Feb 2018; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT03859141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859141.